PACIFIC-8: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

The pharmacokinetics (PK) of Durvalumab and Domvanalimab as determined by concentration

The immunogenicity of Durvalumab and domvanalimab as assessed by presence of Anti-Drug Antibodies (ADAs)

Defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review (BICR), or death due to any cause in participants with PD-L1 TC ≥ 1%

Overall Survival (OS)

Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR

Duration of Response (DoR) using BICR assessment according to RECIST 1.1

Time from randomization to second progression (PFS2)

Time from randomization until the first date of distant metastasis or death in the absence of distant metastasis (TTDM).

Time to first subsequent therapy (TFST)

PFS at 6, 12, 18 and 24 months (proportion per Kaplan-Meier)

Time to deterioration in pulmonary symptoms (TTFCD)

Defined as time from randomisation until progression per RECIST 1.1 as assessed by Investigator or death due to any cause in participants

Overall Survival (OS) at 24 months